Table 1 Patient characteristics and biological parameters on the day of pharmacokinetic monitoring

Age (years)

36.3 ± 6.70

34.7 ± 6.92

0.643

Sex

 Male

6/9

2/7

0.131

 Female

3/9

5/7

Weight (kg)

51 ± 11.88

49.7 ± 8.80

0.832

Body mass index (BMI)

18.0 ± 3.74

17.1 ± 2,37

0.604

Dose of lopinavir (mg)/kg/12 h

8.07 ± 1.41

8. 51 ± 1.44

Dose of ritonavir (mg)/kg/12 h

2.02 ± 0.35

2.13 ± 0.36

Laboratory parameters

 Haemoglobin (g/dL)

10.3 ± 3.58

9.8 ± 1.45

0.802

 Leucocytes (10³/mL)

4960 ± 3050

3900 ± 1643

0.554

 Neutrophils (10³/mL)

3890 ± 1935

3956 ± 2985

 Lymphocytes (10³/mL)

1420 ± 837

1375 ± 801

0.937

 Monocytes (10³/mL)

260 ± 89

225 ± 189

0.722

 AST (U/L)

61.8 ± 20.31

48.2 ± 37.44

0.507

 ALT (U/L)

49.4 ± 34.28

30 ± 22.31

0.363

 Creatinine (µmol/L)

102.2 ± 27.54

106.1 ± 62.01

0.926

 Total cholesterol (mmol/L)

162 ± 29.10

104.3 ± 58.44

0.200

 HDL cholesterol (mmol/L)

24.3 ± 10.26

23 ± 9.89

0.894

 Amylasaemia (U/L)

116.6 ± 18.03

98 ± 56.78

0.616

 Total bilirubin (µmol/L)

6.2 ± 2.70

9.2 ± 4.80

0.360

 Direct bilirubin (µmol/L)

0.87 ± 1.02

2.75 ± 2.33

0.213

 Lymphocytes TCD4 (cells/µL)

221.1 ± 154.75

285.8 ± 175.39

0.446

Type of tuberculosis

 SPPT

7/9

7/7

0.475

 SNPT

2/9

0/7)

–

WHO HIV stage

 Stage 2

1/9

0/7

0.562

 Stage 3

8/9

7/7